Below we look at the regional trends from the just published DB6 data on the performance of the global CHC market in 2021, showing how an upturn in Asia-Pacific helped global growth accelerate to 4.8% in the full-year period.
Europe (+3.3%) was the slowest growing region globally, although this does reflect an upturn vs 2020, thanks to robust growth in gastrointestinals (+6.1%) and a return to growth for cough, cold & allergy (+2.4%). Largest market Germany (-0.6%) saw its decline soften, while other Big 5 Western European markets rebounded to growth. Notably, Russia has fallen down the rankings from No.2 to No.4 in Europe, largely driven by devaluation of the Rouble, coupled with a flat year-end result (+1.8%)
Asia-Pacific (+5.6%) had a buoyant performance vs 2020, attributed to advances in largest market China (+6.9%) and a softening decline for No.2 ranked Japan (-1.2%), these markets have a combined share of almost 70% of total regional sales. Sales in China have rebounded somewhat, as harsh Covid restrictions generated a relatively weak 2020 comparator. Despite intermittent restrictions continuing, a relatively free environment has boosted sales across most major categories as consumers seek to remedy all ailments.
Americas (+4.9%) saw a slowdown vs 2020; the US market (+3.9%) has gained momentum throughout the year – finishing well, albeit slower than 2020 – thanks to a robust cough cold & allergy uptick (+6.5%) and notable increases in Lifestyle CHC (+10.8%) and gastrointestinals (+8.9%), more than offsetting the slowdown in VMS and decline in dermatologicals.
In Latin America, leading market Brazil (+11.7%) advanced thanks to double-digit increases in VMS (+16.2%), cough, cold & allergy (+11.6%) and Lifestyle CHC (+11%).
One of the core benefits of your OTC DASHBOARD subscription is unrivalled coverage of the OTC market in the Middle East & Africa. Sales in this region now total US$8.8bn, following an impressive 6.7% upturn in 2017, and below we highlight some of the key recent trends & developments in this dynamic region.
Two of the region’s Top 5 markets, Turkey and South Africa, feature in the global Top 20 and both outpaced the regional trend in 2017. Turkey’s OTC market was particularly dynamic, partly driven by price inflation but also rising volume sales, thanks to growth in consumer spending and also strong investment from multinational OTC marketers, who compete with well-established local companies like Abdi Ibrahim and Santa Farma.
As well as double-digit growth in Turkey, where Bayer is the No.1 marketer, there were also strong performances from Algeria (+10.0%), Egypt (+16.4%) and Nigeria (+8.2%). GSK occupies a strong position in Egypt and Nigeria, thanks largely to the popularity of painkillers such as Panadol, and is committed to expanding its OTC portfolio and widening distribution.
Sanofi is the leading OTC marketer in Algeria, again thanks to a well-established analgesics portfolio (Doliprane and Aspegic), in addition to a fast-growing CCA range. Overall, GSK, Sanofi and Bayer are the standout OTC marketers in the region, joined by South Africa’s No.1 Adcock Ingram and RB.
For a deep dive into our Q4 2017 data and trend reporting on all Middle East & Africa markets, be sure to log on to the OTC DASHBOARDwebsite or app (which can be downloaded on Apple or Android smartphones).
As part of its ongoing commitment to Africa, J&J has announced the launch of the Africa Innovation Challenge. The project will support Africa’s growing ecosystem and help develop consumer health solutions for local towns.
Earlier this year, J&J announced its global public health strategy in Cape Town, South Africa. The operations expand upon the company’s presence in Africa, which began in 1936.
“Our goal is to improve the health and wellbeing of families and communities around the world,” said Josh Ghaim, J&J’s Chief Technology Officer, Consumer R&D. “With its focus on consumer healthcare, the Africa Innovation Challenge will help to surface important issues impacting local communities. We look forward to engaging with the continent’s top entrepreneurs and scientists, and through collaboration, helping advance their ideas and bringing meaningful solutions across three very important healthcare areas.”
The Africa Innovation Challenge seeks ideas focused on three critical health areas, promoting early child development and maternal health; empowering young women; and improving family wellbeing.
Challenge participants with successful solutions will receive up to US$100,000 in funding and mentorship from scientists, engineers and researchers in the J&J Consumer Research & Development organisation.
The news of J&J’s latest innovative challenge comes alongside the recent decision to drop ‘McNeil’ from their OTC business name, opting for J&J Consumer instead.
To apply to the challenge and review the applicable terms and conditions, please visit the Africa Innovation Challenge website. The deadline to submit applications is 17th January 2017.
OTC DASHBOARD is your sole Nicholas Hall & Company source of regular updates on the OTC market in Africa and the Middle East. Explore our Rest of World section for the latest content.